Literature DB >> 25281010

Validation of clinical symptom IRT scores for diagnosis and severity assessment of common mental disorders.

Elena Olariu1, José-Ignacio Castro-Rodriguez, Pilar Álvarez, Carolina Garnier, Marta Reinoso, Luis Miguel Martín-López, Jordi Alonso, Carlos G Forero.   

Abstract

PURPOSE: We studied the validity and responsiveness of an item response theory (IRT) scoring method for assessing major depressive episode (MDE) and generalized anxiety disorder (GAD) severity based on direct assessment of DSM-IV-TR symptoms.
METHODS: Prospective cohort study (baseline, 1-month, 3-months assessments) of patients seeking help for incident or aggravated mood or anxiety symptoms from primary, outpatient and inpatient mental health centers (N = 244; 67.81 % active cases - 100 % under psychiatric treatment). The drop-out rate at 3 months was 24.89 %. Patients were assessed at each follow-up for presence/absence of DSM-IV symptoms of MDE (nine symptoms) and GAD (eight symptoms). IRT scores for depression (INS-D) and anxiety (INS-G), based on response patterns, were obtained by means of a 2-parameter model. Diagnostic accuracy was assessed with receiver operating characteristic analysis, using a blinded MINI interview as gold standard. Scores' construct validity was compared with external clinician-administered (Hamilton Depression Rating Scale, HRSD; Hamilton Anxiety Rating Scale, HAM-A) and self-reported severity measures (PHQ-9; Beck Anxiety Inventory-Subjective Aspects, BAI-Sub). Responsiveness was analyzed based on the evolution of HRSD and HAM-A scores.
RESULTS: Both severity scores showed excellent reliability (INS-D: 0.92; INS-G: 0.93) and yielded high diagnostic accuracy (INS-D: AUC = 0.96; INS-G: AUC = 0.91) with respect to MINI diagnoses. INS-D and INS-G had higher correlations with clinician-administered measures of the same disorder (INS-D-HRSD: 0.73; INS-G-HAM-A: 0.53) than with self-reported measures (INS-D-PHQ-9: 0.69; INS-G-BAI-Sub: 0.49). Patients who recovered during follow-up showed important decreases in severity (Cohen's d INS-D:-1.38; INS-G: -1.75). About 90 % variance of INS-D and INS-G score changes over time was associated with changes in clinical status.
CONCLUSIONS: INS-D and INS-G are short reliable, valid, and responsive measures that can be used for diagnostic and severity assessment of mood and anxiety disorders in outpatient care.

Entities:  

Mesh:

Year:  2014        PMID: 25281010     DOI: 10.1007/s11136-014-0814-5

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  49 in total

Review 1.  Methods for assessing responsiveness: a critical review and recommendations.

Authors:  J A Husted; R J Cook; V T Farewell; D D Gladman
Journal:  J Clin Epidemiol       Date:  2000-05       Impact factor: 6.437

2.  Loss to follow-up in cohort studies: how much is too much?

Authors:  Vicki Kristman; Michael Manno; Pierre Côté
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

3.  Mental disorders in primary care: prevalence and co-morbidity among disorders. results from the functional illness in primary care (FIP) study.

Authors:  Tomas Toft; Per Fink; Eva Oernboel; Kaj Christensen; Lisbeth Frostholm; Frede Olesen
Journal:  Psychol Med       Date:  2005-08       Impact factor: 7.723

Review 4.  Screening for psychiatric disorders in primary care.

Authors:  Jerry Halverson; Carlyle Chan
Journal:  WMJ       Date:  2004

5.  Is major depression adequately diagnosed and treated by general practitioners? Results from an epidemiological study.

Authors:  Anna Fernández; Alejandra Pinto-Meza; Juan Angel Bellón; Pere Roura-Poch; Josep M Haro; Jaume Autonell; Diego José Palao; María Teresa Peñarrubia; Rita Fernández; Elena Blanco; Juan Vicente Luciano; Antoni Serrano-Blanco
Journal:  Gen Hosp Psychiatry       Date:  2010-01-12       Impact factor: 3.238

6.  Duloxetine in treatment of anxiety symptoms associated with depression.

Authors:  David L Dunner; David J Goldstein; Craig Mallinckrodt; Yili Lu; Michael J Detke
Journal:  Depress Anxiety       Date:  2003       Impact factor: 6.505

Review 7.  Combined pharmacotherapy and psychological treatment for depression: a systematic review.

Authors:  Sandro Pampallona; Paola Bollini; Giuseppe Tibaldi; Bruce Kupelnick; Carmine Munizza
Journal:  Arch Gen Psychiatry       Date:  2004-07

8.  Quality of life and functional health of primary care patients.

Authors:  G R Parkerson; W E Broadhead; C K Tse
Journal:  J Clin Epidemiol       Date:  1992-11       Impact factor: 6.437

9.  Sampling and methods of the European Study of the Epidemiology of Mental Disorders (ESEMeD) project.

Authors:  J Alonso; M C Angermeyer; S Bernert; R Bruffaerts; T S Brugha; H Bryson; G de Girolamo; R Graaf; K Demyttenaere; I Gasquet; J M Haro; S J Katz; R C Kessler; V Kovess; J P Lépine; J Ormel; G Polidori; L J Russo; G Vilagut; J Almansa; S Arbabzadeh-Bouchez; J Autonell; M Bernal; M A Buist-Bouwman; M Codony; A Domingo-Salvany; M Ferrer; S S Joo; M Martínez-Alonso; H Matschinger; F Mazzi; Z Morgan; P Morosini; C Palacín; B Romera; N Taub; W A M Vollebergh
Journal:  Acta Psychiatr Scand Suppl       Date:  2004

10.  Implementing a knowledge application program for anxiety and depression in community-based primary mental health care: a multiple case study research protocol.

Authors:  Pasquale Roberge; Louise Fournier; Hélène Brouillet; Catherine Hudon; Janie Houle; Martin D Provencher; Jean-Frédéric Lévesque
Journal:  Implement Sci       Date:  2013-03-04       Impact factor: 7.327

View more
  2 in total

1.  Change in functioning outcomes as a predictor of the course of depression: a 12-month longitudinal study.

Authors:  Carlos G Forero; Elena Olariu; Pilar Álvarez; José-Ignacio Castro-Rodriguez; Maria Jesús Blasco; Gemma Vilagut; Víctor Pérez; Jordi Alonso
Journal:  Qual Life Res       Date:  2018-04-10       Impact factor: 4.147

2.  Aripiprazole Improves Associated Comorbid Conditions in Addition to Tics in Adult Patients with Gilles de la Tourette Syndrome.

Authors:  Sarah Gerasch; Ahmad Seif Kanaan; Ewgeni Jakubovski; Kirsten R Müller-Vahl
Journal:  Front Neurosci       Date:  2016-09-12       Impact factor: 4.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.